New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 30, 2014
07:18 EDTBAXBaxter restructures agreement with Xenetic Biosciences
Baxter International announced it has restructured its ongoing agreement with Xenetic Biosciences for the development of BAX 826, a recombinant Factor VIII treatment for hemophilia A under investigation to assess its potential to extend the half-life and duration of effectiveness. This program complements the company’s current development programs, which are focused on improving the pharmacokinetic profile and extending the half-life of blood coagulation factors, including Factor VIII. Xenetic and Baxter previously established an exclusive worldwide agreement to develop novel forms of polysialylated blood coagulation factors, including Factor VIII, using Xenetic’s proprietary polysialic acid technology. Under the terms of the restructured arrangement, Baxter will make an equity investment in the common stock of Xenetic and has agreed to make contingent milestone payments as well as pay royalties on future sales. Baxter recently announced the completion of enrollment in a Phase III clinical trial of BAX 855, its investigational, extended half-life, recombinant Factor VIII treatment for hemophilia A. The company continues to expect to file for regulatory approval for BAX 855 in the United States by the end of 2014. The company also said a Phase I/II open-label clinical trial to assess the safety and optimal dosing schedule of BAX 335, an investigational Factor IX gene therapy treatment for hemophilia B, is underway and the first patients have been dosed.
News For BAX From The Last 14 Days
Check below for free stories on BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
09:15 EDTBAXBaxter says 'feels good' about guidance
Subscribe for More Information
08:56 EDTBAXBaxter: Guidance contemplates possible headwinds related to cyclo competition
Subscribe for More Information
07:05 EDTBAXBaxter sees Q3 EPS before special items $1.28-$1.32, consensus $1.32
The company said, "For Q3, the company expects sales growth of approximately 12%-13%, excluding the impact of foreign currency. TheQ3 earnings guidance excludes approximately 7c per diluted share of projected intangible asset amortization expense."
07:04 EDTBAXBaxter narrows FY14 adjusted EPS view to $5.10-$5.20, consensus $5.15
Subscribe for More Information
07:02 EDTBAXBaxter reports Q2 adjusted EPS $1.26, consensus $1.22
Reports Q2 revenue $4.26B, consensus $4.12B.
07:01 EDTBAXBaxter confirms FY14 outlook
Subscribe for More Information
July 16, 2014
15:27 EDTBAXNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use